ALSO NOTED: Did Merck, Schering withhold Zetia data?;Genentech gives eye docs access to Avastin

> Merck and Schering-Plough research raised questions about potential liver damage from their popular cholesterol med Zetia--but the companies never published those studies. News about this unpublished data comes on the heels of a delay in results from an important new Zetia trial. Report

> Genentech and its eye-doctor critics have buried the hatchet, at least partly. The company will allow ophthalmologists to order its cancer drug Avastin from wholesalers and then send it to compounding pharmacies to be repackaged for use against macular degeneration. Report

> Massachusetts has pledged $40.5 million in incentives to Shire, to persuade the British drug maker to follow through on an expansion project in Lexington that would create hundreds of jobs. Report

> The European Commission is on the verge of handing $2.9 billion to the Innovative Medicines Initiative, which will pair up with academics and pharma industry types to develop new drugs. Release

> Abbott Laboratories got the regulatory nod to sell its psoriasis treatment Humira in Europe. Report

> Millennium Pharmaceuticals filed for FDA approval to market Velcade for previously untreated multiple myeloma. Release

And Finally... Do we need drugs for shyness, or do shy folks just need practice making conversation? Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.